Capella Imaging

Capella Imaging is a private, pre-clinical stage biotech developing targeted diagnostic imaging agents, with a primary focus on cardiovascular thrombus detection. The company's lead program, FibroScint (Tc-99m F4A), is a peptide-based radiopharmaceutical designed for SPECT imaging of fibrin, a key component of blood clots. Initial development is targeting the orphan indication of thrombus in LVAD patients, a population with significant unmet diagnostic needs and high complication rates from anticoagulation therapy. The founding team combines deep expertise in radiopharmaceutical chemistry, cardiology, and nanomedicine.

Development of peptide-based, molecularly targeted diagnostic imaging agents, specifically radiopharmaceuticals for SPECT imaging. The platform involves conjugating targeting peptides (e.g., fibrin-targeting) with the radioisotope Technetium-99m.

The competitive landscape for fibrin-specific imaging agents is not crowded, particularly for LVAD applications. However, Capella may face competition from other molecular imaging approaches (e.g., PET agents) and from advances in non-imaging biomarkers or device monitoring technologies. Established radiopharmaceutical companies could develop competing agents if the market opportunity is validated.